NCT03097341View on ClinicalTrials.gov

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions
Thrombosis
Interventions
DRUG

xisomab 3G3- Dose 1

Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.

DRUG

xisomab 3G3-Dose 2

Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.

DRUG

xisomab 3G3-Dose 3

Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.

DRUG

xisomab 3G3- Dose 4

Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.

OTHER

Placebo

Participants will receive a single intravenous dose of placebo.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Aronora, Inc.
All Listed Sponsors
lead

Aronora, Inc.

INDUSTRY

NCT03097341 - Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter